monooxygenase DBH like 1Genealiases: MOX · PRO5780 · dJ248E1.1
Q-omics provides the consensus-scored MOXD1 profile across patient tissues and cancer cell-line models. MOXD1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MOXD1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, MOXD1 protein abundance shows 27,873 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where MOXD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MOXD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MOXD1 survival associations across molecular data types. MOXD1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MOXD1 RNA expression–survival associations across cancer types. High MOXD1 expression shows unfavorable associations in UVM, LGG, BLCA and KIRP, but favorable associations in HNSC and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MOXD1 RNA expression.
This table summarizes MOXD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MOXD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MOXD1 shows lower tumor expression in KIRC, KICH, KIRP and BLCA and higher tumor expression in BRCA and LUAD. The KIRC box plot shows higher MOXD1 RNA expression in normal versus tumor tissue (log2 FC = −2.812, t-test p < 0.001).
This table shows molecular features associated with MOXD1 in patient tissues and cancer cell lines. In patient samples, MOXD1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MOXD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
